Stage III unresectable or histologically confirmed stage IV cutaneous melanoma (melanoma of unknown origin is accepted), treatment naïve (metastatic stage) and for which immunotherapy will be started
Performance Status ≤1
BRAF status available; BRAF status determination is required but patient will be eligible regardless of BRAF status
For women of childbearing potential, effective contraception must be initiated during the study.
Patient affiliated to social security plan
Patient having signed informed consent
You may not be if
Breastfeeding or pregnant patients: for women of childbearing age, a urine pregnancy test will be performed
Patients with ocular or mucosal melanoma of metastatic ocular melanoma
Patients with metastatic melanoma not treated with immunotherapy (i.e. treated with a combination of targeted therapies).
Contraindication to the initiation of immunotherapy: HIV and/or HCV and/or HBV positive, active autoimmune disease (chronic inflammatory bowel disease such as ulcerative colitis, Crohn's disease, vasculitis, etc.), patients with autoimmune motor neuropathy (such as Guillain Barré syndrome).
Vulnerable patients: minors, adults under guardianship or curatorship, deprived of liberty
Vulnerable persons (minors, patients under guardianship or curatorship, deprived of liberty, under court protection, etc.).
A psychiatric or addiction history that will compromise the patient's ability to consent and follow the proper protocol procedures
Any other clinical finding that, in the opinion of the principal investigator, could interfere with the results of the study or pose a risk to the patient during the study.
Clareo Health | Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma
